Exploitation of platelets for antitumor drug delivery and modulation of the tumor immune microenvironment

Abstract

Platelets are blood components traditionally believed to have fundamental roles in vascular hemostasis and thrombosis. In recent years, platelets have received new attention for their roles in tumorigenesis and progression. On the one hand, platelets are actively recruited by various tumors and comprise a crucial part of the tumor microenvironment (TME), thus inspiring the use of platelets for tumor-targeted drug delivery. To this end, various platelet-based devices have been proposed, such as natural platelets, engineered platelets, platelet membranes, and platelet-derived microparticles. On the other hand, platelets are involved in tumor immunosuppression mechanisms, by directing and/or assisting various tumor-associated immune cells. However, in the context of inflammation and autoimmune diseases, platelets can amplify immune responses by promoting immune cell mobilization and activation, thereby exacerbating tissue damage. Thus, interest is growing in the use of tumor-associated platelets as targets for therapeutic modulation of the TME and augmenting anti-tumor immune responses. In this review, we summarize current advances in exploiting platelets for both antitumor drug delivery and immune modulation of the TME.

Development and validation of a nomogram to predict overall survival in patients with glioma: a population-based study

“…Chemotherapy is an important tool in the treatment of glioma, especially for patients unable to undergo surgery. Chemotherapy can kill the tumor cells that remain after surgery, thus prolonging the progression-free survival and overall survival of patients [ 28 – 30 ]. Moreover, glioma patients’ poor prognosis was independently associated with both divorce and widowhood.…”